Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Bio-Thera Solutions,Ltd.
  6. Summary
    688177   CNE100003R98

BIO-THERA SOLUTIONS,LTD.

(688177)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancials 
Quotes 5-day view   End-of-day quote. End-of-day quote Shanghai Stock Exchange
05/12/2021 05/13/2021 05/14/2021 05/17/2021 05/18/2021 Date
23.21 23.62 23.63 24.08 28.19 Last
566595 917618 660997 807725 5498409 Volume
+1.44% +1.77% +0.04% +1.90% +17.07% Change
Financials
Sales 2019 0,70 M 0,11 M 0,11 M
Net income 2019 -1 023 M -159 M -159 M
Net Debt 2019 62,5 M 9,73 M 9,73 M
P/E ratio 2019 -
Yield 2019 -
Sales 2020 183 M 28,5 M 28,5 M
Net income 2020 -513 M -79,9 M -79,9 M
Net cash position 2020 1 239 M 193 M 193 M
P/E ratio 2020 -25,0x
Yield 2020 -
Capitalization 9 971 M 1 549 M 1 552 M
EV / Sales 2019 -
EV / Sales 2020 65,2x
Nbr of Employees 825
Free-Float 30,4%
More Financials
Company
Bio-Thera Solutions, Ltd. is a China-based company mainly engaged in the research and development of innovative drugs and biosimilars. The Company is committed to the development of a new generation of antibody drugs to treat cancer, autoimmune diseases, cardiovascular diseases and other major diseases that endanger human life and health. The Company's main products include adalimumab BAT1406, bevacizumab BAT1706,... 
More about the company
All news about BIO-THERA SOLUTIONS,LTD.
04/08Biogen Licenses Actemra Biosimilar Candidate From Bio-Thera Solutions
DJ
01/28BIO-THERA SOLUTIONS  : Announces FDA Accepts Biologics License Application for B..
BU
01/21BIO THERA  : Announces Initiation of Phase I Clinical Trial for BAT1308, a Monoc..
BU
2020BIO-THERA SOLUTIONS  : Partners with Biomm to Market BAT1706 in Brazil
BU
2020BIO-THERA SOLUTIONS  : Submits Marketing Authorization Application (MAA) for BAT..
BU
2020BIO THERA  : and BeiGene Announce License, Distribution, and Supply Agreement fo..
AQ
2020AstraZeneca bets up to $6 billion on new Daiichi cancer drug
RE
2020AstraZeneca bets up to $6 billion on new Daiichi cancer drug
RE
2020BIO-THERA SOLUTIONS  : Partners with Pharmapark to Market BAT2506 in Russia and ..
BU
2020BIO THERA  : NMPA Accepts Bio-Thera Solutions' Biologics License Application (BL..
BU
More news
News in other languages on BIO-THERA SOLUTIONS,LTD.

- No features available -

More news
Chart BIO-THERA SOLUTIONS,LTD.
Duration : Period :
Bio-Thera Solutions,Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIO-THERA SOLUTIONS,LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Managers and Directors
NameTitle
Sheng Feng Li General Manager & Executive Director
Xian Hong Zhan Chief Financial Officer
Xian Zhong Yi Chairman
Xiao Yun Wu Chairman-Supervisory Board, Senior R&D Director
Xian Ming Huang Director & Vice President-Antibody R&D
Sector and Competitors
1st jan.Capitalization (M$)
BIO-THERA SOLUTIONS,LTD.-25.69%1 549
GILEAD SCIENCES, INC.17.63%86 626
WUXI APPTEC CO., LTD.13.72%60 935
VERTEX PHARMACEUTICALS-8.46%56 006
REGENERON PHARMACEUTICALS6.94%54 236
BIONTECH SE143.25%47 894